JP2009519985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519985A5 JP2009519985A5 JP2008546216A JP2008546216A JP2009519985A5 JP 2009519985 A5 JP2009519985 A5 JP 2009519985A5 JP 2008546216 A JP2008546216 A JP 2008546216A JP 2008546216 A JP2008546216 A JP 2008546216A JP 2009519985 A5 JP2009519985 A5 JP 2009519985A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pyrimidin
- isopropyl
- methyl
- methylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 11
- 229920002261 Corn starch Polymers 0.000 claims 11
- 239000008120 corn starch Substances 0.000 claims 11
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 239000008101 lactose Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 3
- 230000003113 alkalizing effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 3
- 229940049654 glyceryl behenate Drugs 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- RWNJOXUVHRXHSD-UHFFFAOYSA-N hept-6-enoic acid Chemical compound OC(=O)CCCCC=C RWNJOXUVHRXHSD-UHFFFAOYSA-N 0.000 claims 2
- SGVASDMKSZUTTN-UHFFFAOYSA-N 7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoic acid Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1C=CC(=O)CC(O)CC(O)=O SGVASDMKSZUTTN-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- SOEGVMSNJOCVHT-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-5-[2-(4-hydroxy-6-oxooxan-2-yl)ethenyl]-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical compound C1C(O)CC(=O)OC1C=CC=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 SOEGVMSNJOCVHT-UHFFFAOYSA-N 0.000 claims 1
- 238000009516 primary packaging Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000013112 stability test Methods 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200500344 | 2005-12-20 | ||
| SIP200500344 | 2005-12-20 | ||
| PCT/EP2006/012180 WO2007071357A2 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519985A JP2009519985A (ja) | 2009-05-21 |
| JP2009519985A5 true JP2009519985A5 (enExample) | 2013-03-28 |
| JP5235676B2 JP5235676B2 (ja) | 2013-07-10 |
Family
ID=37866173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546216A Expired - Fee Related JP5235676B2 (ja) | 2005-12-20 | 2006-12-18 | （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090093499A1 (enExample) |
| EP (1) | EP1968593B1 (enExample) |
| JP (1) | JP5235676B2 (enExample) |
| CN (1) | CN101330919B (enExample) |
| AU (1) | AU2006329006B2 (enExample) |
| BR (1) | BRPI0620629B8 (enExample) |
| CA (1) | CA2630704C (enExample) |
| EA (1) | EA015682B1 (enExample) |
| WO (1) | WO2007071357A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008036286A1 (en) | 2006-09-18 | 2008-03-27 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
| EP2285353A1 (en) * | 2008-01-30 | 2011-02-23 | Lupin Limited | Modified release formulations of hmg coa reductase inhibitors |
| EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
| HRP20180077T1 (hr) * | 2008-06-27 | 2018-02-23 | Krka, Tovarna Zdravil D.D., Novo Mesto | Farmaceutski sastav koji sadrži statin |
| PL386051A1 (pl) * | 2008-09-09 | 2010-03-15 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego |
| TR200902077A2 (tr) | 2009-03-17 | 2010-01-21 | Sanovel İlaç San.Veti̇c.A.Ş. | Stabil rosuvastatin kompozisyonları |
| RU2606592C1 (ru) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты) |
| AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer Inc. | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| EP1368000A4 (en) * | 2001-03-13 | 2004-12-01 | Penwest Pharmaceuticals Co | CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID |
| SE0101329D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Pharmaceutical formulation |
| GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
| WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| CA2483099A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| WO2005040134A1 (en) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| CA2546894C (en) * | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
| EP1709008A1 (en) * | 2004-01-19 | 2006-10-11 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
-
2006
- 2006-12-18 EP EP06829701.9A patent/EP1968593B1/en not_active Not-in-force
- 2006-12-18 WO PCT/EP2006/012180 patent/WO2007071357A2/en not_active Ceased
- 2006-12-18 CN CN2006800476115A patent/CN101330919B/zh not_active Expired - Fee Related
- 2006-12-18 CA CA2630704A patent/CA2630704C/en not_active Expired - Fee Related
- 2006-12-18 US US12/158,413 patent/US20090093499A1/en not_active Abandoned
- 2006-12-18 AU AU2006329006A patent/AU2006329006B2/en not_active Ceased
- 2006-12-18 EA EA200801447A patent/EA015682B1/ru not_active IP Right Cessation
- 2006-12-18 BR BRPI0620629A patent/BRPI0620629B8/pt not_active IP Right Cessation
- 2006-12-18 JP JP2008546216A patent/JP5235676B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210228722A1 (en) | Quinoline derivative-containing pharmaceutical composition | |
| CN100528161C (zh) | 药物组合物 | |
| RU2016123828A (ru) | Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин | |
| KR20150016280A (ko) | 신규 제형 | |
| TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
| JP5988963B2 (ja) | ピタバスタチン含有製剤及びその製造方法 | |
| TWI811195B (zh) | 包含兩種不同活性原料的醫藥組成物及其製備方法 | |
| JP6243265B2 (ja) | ロスバスタチン含有医薬製剤 | |
| JP2009519985A5 (enExample) | ||
| JP5235676B2 (ja) | （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物 | |
| JP2020059742A (ja) | ロスバスタチンカルシウムを含有する錠剤 | |
| JP2016033133A (ja) | モンテルカストナトリウム製剤 | |
| CN112274487A (zh) | 一种瑞舒伐他汀钙药物制剂 | |
| JP6750785B2 (ja) | 安定なロスバスタチンカルシウム錠剤 | |
| JP6573098B2 (ja) | 安定なロスバスタチンカルシウム錠剤 | |
| JP6339800B2 (ja) | ミグリトール含有コーティング製剤 | |
| MX2008008192A (en) | Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino]pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid |